ライフサイエンスコーパス: HIV vaccine

1 ion can help guide the rational design of an HIV vaccine.

2 mportant for the development of an effective HIV vaccine.

3 ologic prime to aid protection by a putative HIV vaccine.

4 ound CD40L serves as a novel adjuvant for an HIV vaccine.

5 to be critical constituents in an effective HIV vaccine.

6 can contribute to the design of an effective HIV vaccine.

7 ccinology offer new promise for an effective HIV vaccine.

8 n (and exclusion) of specific epitopes in an HIV vaccine.

9 odeled after the moderately protective RV144 HIV vaccine.

10 rotective responses elicited by an effective HIV vaccine.

11 ent a beneficial component of an efficacious HIV vaccine.

12 o accelerate the development of an effective HIV vaccine.

13 ion and to aid in the design of an effective HIV vaccine.

14 e development of an effective antibody-based HIV vaccine.

15 ons for the continued quest for an effective HIV vaccine.

16 offers great promise for advancing toward an HIV vaccine.

17 entual design of an effective antibody-based HIV vaccine.

18 a daunting problem for the development of an HIV vaccine.

19 nses that might be desirable in a protective HIV vaccine.

20 the development of an effective and durable HIV vaccine.

21 HIV presents a key challenge for creating an HIV vaccine.

22 rus (HIV) immune responses is the goal of an HIV vaccine.

23 ve promise to assist in the development of a HIV vaccine.

24 promise as a unique approach to an effective HIV vaccine.

25 ration are relevant to the development of an HIV vaccine.

26 operty is a high priority when developing an HIV vaccine.

27 rtant in selecting candidate epitopes for an HIV vaccine.

28 tem and our best hope of finally creating an HIV vaccine.

29 nd the focus for design of an antibody-based HIV vaccine.

30 iasm for a neutralizing antibody (nAb)-based HIV vaccine.

31 controllers may hold the key to an effective HIV vaccine.

32 bodies is critical for the development of an HIV vaccine.

33 otential to be developed into a prophylactic HIV vaccine.

34 on against further use of the Ad5 vector for HIV vaccines.

35 e targets that would augment the efficacy of HIV vaccines.

36 de important insights for the development of HIV vaccines.

37 l challenge in the preclinical evaluation of HIV vaccines.

38 pment of next-generation vaccines, including HIV vaccines.

39 ent RV144 clinical trial, which combined two HIV vaccines.

40 development of therapeutic and preventative HIV vaccines.

41 be considered a new approach for preventive HIV vaccines.

42 on, which has implications for the design of HIV vaccines.

43 st new strategies for design and delivery of HIV vaccines.

44 eveloping antigens that could serve as novel HIV vaccines.

45 inging new insights for the design of future HIV vaccines.

46 etect critical T cell responses to candidate HIV vaccines.

47 tective immunity essential for the design of HIV vaccines.

48 anism for reduced activity of Env-containing HIV vaccines.

49 se progression and the potential efficacy of HIV vaccines.

50 e epitopes, and are not part of most current HIV vaccines.

51 lymphocyte epitopes for inclusion in future HIV vaccines.

52 bject of intense study in efforts to produce HIV vaccines.

53 l in the design of stabilized envelope-based HIV vaccines.

54 newing hope of developing carbohydrate-based HIV vaccines.

55 ortant new direction in future design of new HIV vaccines.

56 a role for eliciting ADCC-mediating IgG1 in HIV vaccines.

57 velopment of a human immunodeficiency virus (HIV) vaccine.

58 y an effective human immunodeficiency virus (HIV) vaccine.

59 The development of a preventative HIV vaccine able to elicit broadly neutralizing antibodi

60 Our results suggest that HIV vaccine adjuvants may differentially modulate immune

61 fficacy trial testing the combination of the HIV vaccines ALVAC-HIV (vCP1521) and AIDSVAX B/E to prev

62 of the urgent need to produce an efficacious HIV vaccine and discuss several crucial issues that must

63 pment has provided renewed impetus toward an HIV vaccine and led directly to the development of novel

64 ransmission and in the design and testing of HIV vaccine and microbicide candidates.

65 understanding of how to design an effective HIV vaccine and novel therapeutics to eliminate the vira

66 he effects of immunization with an exogenous HIV vaccine and pulse exposure to the subject's unique v

67 ral blood B cells of recipients of the RV144 HIV vaccine and showed that these antibodies neutralized

68 e essential for designing carbohydrate-based HIV vaccines and antiviral agents.

69 hich should inform the design of efficacious HIV vaccines and immunotherapies.

70 le to provide a platform to assess candidate HIV vaccines and other immunotherapeutic strategies.

71 need to be answered to develop a protective HIV vaccine, and the immediate need to harness a much br

72 urfaces, FcRn might be useful for delivering HIV vaccine antigens across mucosal epithelial barriers

73 Current human immunodeficiency virus (HIV) vaccine approaches emphasize prime boost strategies

74 Many candidate HIV vaccines are designed to primarily elicit T cell res

75 e-vector-based human immunodeficiency virus (HIV) vaccines are an integral part of a number of HIV va

76 challenges for the development of paediatric HIV vaccines; available vaccines and completed or planne

77 erous attempts over many years to develop an HIV vaccine based on classical strategies, none has conv

78 Based on the increased number of HIV vaccines being tested globally, it is essential to d

79 A mimic-based human immunodeficiency virus (HIV) vaccine can be a viable alternative to carbohydrate

80 In this study, a canarypox HIV vaccine candidate vector expressing HIV gag and env

81 protein warrants further investigation as an HIV vaccine candidate, as a stand-alone protein, or as a

82 Here, we generated two poxvirus-based HIV vaccine candidates (NYVAC and ALVAC vectors) express

83 c community exploring the discovery of novel HIV vaccine candidates and therapeutic targets.

84 c community exploring the discovery of novel HIV vaccine candidates and therapeutic targets.

85 tively, the findings may permit selection of HIV vaccine candidates eliciting innate immune response

86 challenges, one of which is the inability of HIV vaccine candidates evaluated thus far to elicit prod

87 We have generated two novel NYVAC-based HIV vaccine candidates expressing HIV-1 clade C trimeric

88 egree to which this problem extends to other HIV vaccine candidates is not known.

89 and b12H mice should be useful in optimizing HIV vaccine candidates to elicit a neutralizing response

90 hlighted the need for further improvement of HIV vaccine candidates, formulation, and vaccine regimen

91 ot protective, and despite immunogenicity of HIV vaccine candidates, human trials have exclusively yi

92 he need for further improvements to evaluate HIV vaccine candidates.

93 ures, provides insights to advance design of HIV vaccine candidates.

94 All current human immunodeficiency virus (HIV) vaccine candidates contain multiple viral component

95 centrations, inspiring efforts to develop an HIV vaccine capable of eliciting bNAb responses.

96 timmunization.IMPORTANCE Attempts to develop HIV vaccines capable of inducing potent and durable B-ce

97 4, they generate testable hypotheses for the HIV vaccine community and they highlight the importance

98 Pediatric HIV vaccines constitute a core component of such efforts

99 zation with neutralizing Abs suggest that an HIV vaccine could be efficacious were it able to elicit

100 A pediatric HIV vaccine could reduce the number of these ongoing inf

101 (Ad5)-vectored human immunodeficiency virus (HIV) vaccine could prevent HIV acquisition and/or reduce

102 Two major challenges in pediatric HIV vaccine design are the competence of the neonatal/in

103 These findings will inform HIV vaccine design by providing testable correlates of p

104 A guiding principle for HIV vaccine design has been that cellular and humoral im

105 Rational HIV vaccine design is crucially dependent on a number of

106 phenotype may provide important insights for HIV vaccine design.

107 ection, which has important implications for HIV vaccine design.

108 opeptides are therefore of great interest in HIV vaccine design.

109 vel approaches to preventive and therapeutic HIV vaccine design.

110 ody responses and therefore crucial for anti-HIV vaccine design.

111 d, protective antibodies remains a hurdle to HIV vaccine design.

112 arch symposium on humanized mouse models for HIV vaccine design.

113 ed individuals, define critical epitopes for HIV vaccine design.

114 replication and further our understanding of HIV vaccine design.

115 ll provide a rational approach for improving HIV vaccine design.

116 rnative and potentially superior approach to HIV vaccine design.

117 pe glycoprotein gp120, is a high priority in HIV vaccine design.

118 on and antibody development is important for HIV vaccine design.

119 re throughout, making it a stable target for HIV vaccine design.

120 that triggered it, providing a template for HIV vaccine design.

121 e engineering of specific Env glycoforms for HIV vaccine design.

122 value of the polyvalent formulation in this HIV vaccine design.

123 e cells has the potential to inform rational HIV vaccine design.

124 -1 infection, with positive implications for HIV vaccine design.

125 ortant goal of human immunodeficiency virus (HIV) vaccine design is identification of strategies that

126 evant issue for candidate germline-targeting HIV vaccine designs because of the in vivo rarity of nai

127 Our data provide important information for HIV vaccine designs that aim for effective and balanced

128 was identified as a potential immunogen for HIV vaccine development and as a potential antiviral age

129 nteraction should be further investigated in HIV vaccine development and other prophylactic vaccine a

130 population should be further investigated in HIV vaccine development as a novel correlate of immunity

131 However, HIV vaccine development has been hampered by significant

132 A central effort in HIV vaccine development is to generate protective broadl

133 system offers new direction and insights for HIV vaccine development with the potential to increase t

134 ibody durability, is the major challenge for HIV vaccine development, regardless of the immunogen or

135 replication provide a useful model to inform HIV vaccine development.

136 carbohydrate-based immunogens and hasten the HIV vaccine development.

137 l basis for gp41 antigen design suitable for HIV vaccine development.

138 g activity of the mAbs, long sought goals in HIV vaccine development.

139 ach to further optimize Env formulations for HIV vaccine development.

140 ly cross-reactive and potentially useful for HIV vaccine development.

141 ling SHIV infection and provide insights for HIV vaccine development.

142 echanism that has been largely overlooked in HIV vaccine development.

143 ade immunogens with the potential to advance HIV vaccine development.

144 lizing antibodies (bNAbs) is a major goal of HIV vaccine development.

145 zing antibodies (bnAbs) is a primary goal of HIV vaccine development.

146 rational design of glycopeptide antigens for HIV vaccine development.

147 e of this unique non-human primate model for HIV vaccine development.

148 ate of HIV-1 control that may be relevant to HIV vaccine development.

149 prioritized such that resources to energize HIV vaccine discovery can be identified.

150 rected at answering fundamental questions in HIV vaccine discovery through laboratory, nonhuman prima

151 relates of protection/immunity' in the RV144 HIV vaccine efficacy trial that are missed by other meth

152 orts of the partially efficacious Thai RV144 HIV vaccine efficacy trial.

153 Human HIV vaccine efficacy trials have not generated meaningfu

154 otential qualifying factor for evaluation of HIV vaccine efficacy.

155 All human immunodeficiency virus (HIV) vaccine efficacy trials to date have ended in failu

156 ase 3 trial of human immunodeficiency virus (HIV)-vaccine efficacy, VAX004.

157 bodies to V2 are also important hallmarks of HIV-vaccine efficacy in humans will require further stud

158 me of neutralization broadening as effective HIV vaccine elements.

159 udovirion particle production by live-vector HIV vaccines enhances HIV-specific cellular and humoral

160 discuss this using the example of the Global HIV Vaccine Enterprise.

161 monoclonal antibodies (MAbs) in the current HIV vaccine field are generated from HIV-1-infected peop

162 CC) responses are of growing interest in the HIV vaccine field but current cell-based assays are usua

163 erved in the RV144 trial, researchers in the HIV vaccine field seek to substantiate and extend the re

164 essful example of reverse vaccinology in the HIV vaccine field with rationally designed epitope scaff

165 pelling rationale to develop safe, effective HIV vaccines for use in infants and children.

166 neutralizing antibodies (bnAbs) is a primary HIV vaccine goal.

167 y neutralizing antibodies (bnAbs) is a major HIV vaccine goal.

168 ely, human trials of immunodeficiency virus (HIV) vaccine have shown only marginal efficacy.

169 anarypox ALVAC-human immunodeficiency virus (HIV) vaccines have been shown to elicit human HIV-specif

170 Human immunodeficiency virus (HIV) vaccines have the potential to improve antiretrovir

171 DNs to boost immune function to enhance anti-HIV vaccine immunogenicity.

172 otential site to target and incorporate into HIV vaccine immunogens.

173 the virus that may be exploited in designing HIV vaccine immunogens.

174 al model to evaluate the added benefit of an HIV vaccine in the context of goals to increase rates of

175 (SHIVs) for the evaluation of candidate anti-HIV vaccines in nonhuman primates.

176 6 vector-based human immunodeficiency virus (HIV) vaccine in humans.

177 effective SIV/human immunodeficiency virus (HIV) vaccine in preclinical testing.

178 cteristics of anti-HIV bNAbs, we designed an HIV vaccine incorporating the molecular adjuvants BAFF (

179 s diseases such as tuberculosis, malaria and HIV, vaccines inducing greater T cell responses are requ

180 Development of an HIV vaccine is critical for control of the HIV pandemic,

181 Development of an HIV vaccine is desperately needed to control new infecti

182 The key to an effective HIV vaccine is development of an immunogen that elicits

183 Development of an HIV vaccine is of vital importance for prevention of new

184 The development of an HIV vaccine is proving to be an unprecedented challenge.

185 A major challenge in the development of an HIV vaccine is that of contending with the extensive seq

186 a broadly neutralizing antibody (bnAb)-based HIV vaccine is the activation of appropriate B cell prec

187 hallenge for the development of an effective HIV vaccine is to elicit neutralizing antibodies against

188 The goal of an HIV vaccine is to generate robust and durable protective

189 At present, the product pipeline for HIV vaccines is insufficient and is limited by inadequat

190 f an effective human immunodeficiency virus (HIV) vaccine is a high global priority.

191 f a successful human immunodeficiency virus (HIV) vaccine is an immunogen that can generate broadly c

192 Developing a human immunodeficiency virus (HIV) vaccine is critical to end the global acquired immu

193 velopment of a human immunodeficiency virus (HIV) vaccine is the use of viral vectors with a proven s

194 development of human immunodeficiency virus (HIV) vaccines is located in the membrane-proximal extern

195 nd therapeutic human immunodeficiency virus (HIV) vaccines is the inability of viral envelope glycopr

196 immunogenic proteins and peptides in future HIV vaccines may act as a critical cornerstone for enhan

197 that induction of this cell subset by future HIV vaccines may be important for narrowing possible rou

198 Our results suggest that an HIV vaccine might be delivered by autologous transplanta

199 s now conceivable that an antibody-dependent HIV vaccine might be possible, given the discovery of HI

200 ll, our results suggest that a well-designed HIV vaccine might both reduce the rate of acquisition an

201 ta suggest that efforts toward developing an HIV vaccine might consider eliciting protective HIV anti

202 -protein boost human immunodeficiency virus (HIV) vaccine modalities as a strategy to induce protecti

203 An effective HIV vaccine must elicit immune responses that recognize

204 ion, candidate human immunodeficiency virus (HIV) vaccines must generate diverse and long-lasting CD8

205 than two decades have not yet resulted in an HIV vaccine of even moderate effectiveness.

206 Our previous studies demonstrated that in an HIV vaccine phase I trial, the DP6-001 trial, a polyvale

207 the lack of efficacy of a recently conducted HIV vaccine phase IIb trial, despite induction of robust

208 f VISP varied substantially across different HIV vaccine product types: 399 of 460 (86.7%; 95% CI, 83

209 ing antibodies are thought to be crucial for HIV vaccine protection, but studies in animal models sug

210 ctive Ab response is considered critical for HIV vaccine protective efficacy.

211 The induction of VISP in HIV vaccine recipients is common, especially with vaccin

212 o track Ag-specific plasmablast responses in HIV-vaccine recipients over a period of 42 d and perform

213 cy trials of adenovirus 5-vectored candidate HIV vaccines [recombinant Ad5 (rAd5)-HIV] were halted fo

214 In this study, we describe a novel HIV vaccine regimen that induces potent IgA responses in

215 a prime-boost human immunodeficiency virus (HIV) vaccine regimen conferred approximately 30% protect

216 Hence, SIV/HIV vaccine regimens comprising CE pDNA prime and CE+gag

217 vaccines are an integral part of a number of HIV vaccine regimens currently under evaluation.

218 The development of an effective HIV vaccine remains a global necessity for preventing HI

219 Abs) has provided an enormous impetus to the HIV vaccine research and to entire immunology.

220 We propose here that HIV vaccine research could greatly benefit from the stud

221 tibodies to HIV has been a major obstacle to HIV vaccine research since the early days of the epidemi

222 ant (CD4BD) of gp120, a central objective in HIV vaccine research, has been alternately ascribed to i

223 rticle summarizes progress and challenges in HIV vaccine research, the priorities arising from a rece

224 ould have important implications for ongoing HIV vaccine research.

225 f new-generation HIV-1 bNAbs has invigorated HIV vaccine research.

226 ralizing antibodies has been a major goal of HIV vaccine research.

227 lizing antibodies (bNAbs) is a major goal in HIV vaccine research.

228 nt toward a need for novel methodologies for HIV vaccine research.

229 our opinion, the major effort for effective HIV vaccine should be concentrated on generating protect

230 d they also contribute to the notion that an HIV vaccine should stimulate the production of ADCC-medi

231 Optimal HIV vaccines should elicit CD8+ T cells specific for HIV

232 HIV vaccines should elicit immune responses at both the

233 These results suggest that HIV vaccines should focus CD8(+) T cell responses on Gag

234 st infection by viruses such as influenza or HIV, vaccines should elicit antibodies that bind conserv

235 wever, three efficacy trials of Ad5-vectored HIV vaccines showed no protection.

236 an important surrogate model for evaluating HIV vaccine strategies.

237 gnificant impact on future public health and HIV vaccine strategies.

238 n of functional gp120-specific antibodies by HIV vaccine strategies.

239 ghts this epitope as an important target for HIV vaccine strategies.

240 evaluation of human immunodeficiency virus (HIV) vaccine strategies in rhesus macaques.

241 challenge in the development of an effective HIV vaccine strategy.

242 that point the way forward for an effective HIV vaccine strategy.

243 the potential target populations for future HIV vaccine studies examined the prevalence of HIV infec

244 me, information about hMabs from other human HIV vaccine studies is very limited.

245 or and insert-specific CD4 T cells in future HIV vaccine studies.

246 potential mechanistic significance in future HIV vaccine studies.

247 hod to generate more diverse SIV strains for HIV vaccine studies.

248 While development of an HIV vaccine that can induce neutralizing antibodies rema

249 ults is in highlighting the rationale for an HIV vaccine that can induce these broad responses.

250 e very strongly, supporting the quest for an HIV vaccine that induces potent bnAbs.

251 ces to the draining lymph nodes may allow an HIV vaccine that produces immunity in these lymph nodes

252 ired to inform the development of a maternal HIV vaccine that will enhance these responses during pre

253 ersonalized approach to a therapeutic T-cell HIV vaccine that would provide antigens with an excellen

254 s and provide guidance in the development of HIV vaccines that effectively block cell-associated HIV

255 p a successful human immunodeficiency virus (HIV) vaccine that is capable of preventing infection.

256 imal model for human immunodeficiency virus (HIV) vaccines that elicit CD8(+) T cell responses.

257 ell specimens from the ALVAC+AIDSVAX (RV144) HIV vaccine trial associated with protective antibody re

258 ine staining (ICS) data set from a published HIV vaccine trial focused on detecting rare, antigen-spe

259 The RV144 HIV vaccine trial included a recombinant HIV glycoprotei

260 Data from the RV144 HIV vaccine trial indicated that gp120 V2 antibodies wer

261 ntive HIV-1 vaccine efficacy trials: (i) the HIV Vaccine Trial Network (HVTN) 502/Step trial, (ii) th

262 The Thai phase 3 HIV vaccine trial RV 144 showed modest efficacy of a vac

263 cited by natural infection or vaccination in HIV vaccine trial subjects.

264 In the RV144 gp120 HIV vaccine trial, decreased transmission risk was corre

265 ol data from the first moderately protective HIV vaccine trial, RV144, pointed to mechanistic insight

266 relate with protection in the only effective HIV vaccine trial, the administration of preformed mucos

267 The results of the RV144 HIV vaccine trial, which demonstrated a rapid waning of

268 ndividuals from HIV acquisition in the RV144 HIV vaccine trial.

269 ble for the protection observed in the RV144 HIV vaccine trial.

270 nism of the protection observed in the RV144 HIV vaccine trial.

271 t diagnostic tool for easy implementation in HIV vaccine trials and blood banks worldwide.

272 METHODS AND HIV Vaccine Trials Network (HVTN) 104 was designed to ev

273 esponse markers as correlates of risk in the HIV Vaccine Trials Network (HVTN) 505 HIV-1 vaccine effi

274 HIV Vaccine Trials Network (HVTN) studies 070 and 080 we

275 inistration order of heterologous vectors in HIV Vaccine Trials Network 078 (HVTN 078), a randomized,

276 HIV Vaccine Trials Network 083 tested whether cellular i

277 The HIV Vaccine Trials Network and the Statistical Center fo

278 Future HIV vaccine trials should recognise potential interactio

279 ding, refining, and improving the outcome of HIV vaccine trials, in which relevant immune responses a

280 , in testing of plasma samples from multiple HIV vaccine trials, uninfected trial participants scored

281 ips among humoral responses elicited in four HIV vaccine trials.

282 de insight into the limited efficacy seen in HIV vaccine trials.

283 ring HLA alleles and host immune genetics in HIV vaccine trials.

284 the interest in inducing such Abs in future HIV vaccine trials.

285 ion of true HIV infections during preventive HIV vaccine trials.

286 volunteers who want to participate in future HIV vaccine trials.

287 protection in human immunodeficiency virus (HIV) vaccine trials are essential to vaccine design.

288 Most of the current HIV vaccines under development use the i.m. route for im

289 The crucial need for a global HIV vaccine underscores the effort to develop vaccines c

290 profile and makes it an attractive candidate HIV vaccine vector.

291 IL-1beta and make it an attractive candidate HIV vaccine vector.

292 ion on the immune response generated by live HIV vaccine vectors has not been established.

293 and CMV, two viruses that have been used as HIV vaccine vectors.

294 ity induced by human immunodeficiency virus (HIV) vaccines, we are developing a protein-based approac

295 Studies suggest that a relevant HIV vaccine will likely need to induce broad cellular an

296 The development of an HIV vaccine will require a more precise understanding of

297 An effective human immunodeficiency virus (HIV) vaccine will likely need to reduce mucosal transmis

298 of native Env.IMPORTANCE Development of any HIV vaccine with a protein component (for either priming

299 e results further support the development of HIV vaccines with modifications in native Env structures

300 ) prime-boost human immuonodeficiency virus (HIV) vaccine, with intramuscular DNA delivery by either